SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?


To: tuck who wrote (605)11/12/2003 2:47:11 PM
From: tuck  Respond to of 897
 
From Briefing.com:

>>12:02PM Vaxgen: Failure of AIDSVAX trial was widely expected (VXGN) 9.19 -0.66: Punk Ziegal says that based on the results of the N. American phase III trial (which were announced in Feb), failure of the AIDSVAX in the Thai Phase III trial was widely expected. Firm reiterates its Buy rating, noting that its financial projections do not include any revs for AIDSVAX. Firm would view weakness in stock as a buying opportunity.<<

Cheers, Tuck